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Arterial hypertension is a common health problem which re-
presents a major risk factor for a variety of diseases like myocardial
infarction or stroke. Since the discovery of Rho-kinases (ROCKs) as
major effectors of the small GTPase RhoA, ROCKs have been
extensively studied in the ﬁeld of cardiovascular research. In smooth
muscle cells, RhoA and ROCKs not only affect actin polymerisation but
regulate a wide range of cellular functions like contraction, migration
and proliferation [1]. Upregulation of the RhoA/ROCK signalling
cascade has been observed in different cardiovascular disorders like
atherosclerosis, pulmonary hypertension and stroke. Furthermore,
RhoA/ROCK seem to have an impact on NO-signalling and vice versa.
This review describes the current understanding of ROCK signalling
especially in smooth muscle cells and highlights the role of ROCKs as
targets for current therapeutic approaches to treat hypertension.2. General information on ROCKs
2.1. Structure and expression of ROCKs
ROCKs are serine/threonine kinases with a molecular mass of
∼ 160 kDa that are expressed in invertebrates (Caenorhabditis elegans,
Drosophila) and in vertebrates (e.g. zebraﬁsh, Xenopus, mouse,
human). Two different ROCK isoforms encoded by two different
genes have been identiﬁed [2–4]. In humans the genes coding for
ROCK I and ROCK II are located on chromosome 18 (18q11.1) and
chromosome 2 (2p24), respectively. In both enzymes the kinasedomain is located at the amino-terminus, followed by a coiled-coil
forming region that contains the Rho-binding domain (RBD; Fig. 1A).
At the carboxy-terminal part of the protein a Pleckstrin-homology
(PH) domain with an internal cystein-rich domain can be found. The
PH domain is supposed to be involved in protein localization.
The amino-acid sequences of the two isoforms ROCK I and ROCK II
have an overall identity of 65%. The identity in the RBD is 58% and the
highest similarity (92%) is found in the kinase domain [3]. The
phylogenetic tree shows that myotonic dystrophy kinase (DMPK),
DMPK-related cell division control protein 42 (Cdc42)-binding
kinases (MRCK) and citron kinase are most closely related to ROCK I
and ROCK II [5].
The mRNAs of ROCK I and II are ubiquitously expressed. While the
ROCK II transcript is preferentially found inmuscle tissue and in brain,
both ROCK isoforms are expressed in vascular smooth muscle and in
heart [3,6,7]. The regulation of ROCK expression has not been studied
in detail but some data show an upregulation of ROCK by angiotensin
II via angiotensin II type 1 (AT1) receptor-mediated pathways. Mice
receiving continuous Ang II administration showed increased amounts
of ROCK in the coronary arteries [8].
In addition to organ distribution the subcellular localization of
ROCKs has been the subject of various investigations. Cell-fractionating
studies showed that ROCKs are mainly distributed in the cytoplasm but
are partially translocated to the peripheral membrane by RhoA
activation [4]. In addition, ROCK II also localises at the vimentin
intermediate ﬁlament network [9] and at actin stress ﬁbers [10].
2.2. Regulation of ROCK activity
As already described, ROCKs contain a kinase domain at the N-
terminus and regulatory RBD and PH domain at the C-terminal part of
Fig. 1. ROCK structure and regulation of activity. (A) The structure of ROCKs. The kinase domain of ROCK is located at the amino terminus of the protein followed by a coiled-coil
forming region containing the Rho-binding domain (RBD). In the carboxyl terminus a pleckstrin-homology (PH) domain with an internal cystein-rich domain (CRD) is situated.
(B) Mechanisms of ROCK activation. In the inactive form the PH and RBD domain bind to the amino terminus of the enzyme, forming an autoinhibitory loop. Upon binding of active,
GTP-bound RhoA to the RBD the conformation opens and gives rise to an active kinase. Similarly, binding of arachidonic acids leads to an open and active conformation of ROCK.
Cleavage of the C-terminus by. caspase-3 (ROCK I) or granzyme B (ROCK II) removes the autoinhibitory part of ROCK and generates a constitutively active kinase.
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autoinhibitory domain because truncated forms of ROCK lacking the
PH- and RBD-domain are constitutively active whereas the C-
terminus expressed in cells acts in a dominant-negative way [11].
Binding of the activated, GTP-bound form of RhoA to the RBD
stimulates ROCK activity by disrupting the self-associative interaction
between the catalytic and the inhibitory domain [12] (Fig. 1B).
However, this stimulatory effect of RhoA on ROCK activity is
moderate, not exceeding 1.5- to 2-fold increase [13]. In addition to
RhoA, some lipids, such as arachidonic acid can effectively stimulate
ROCK activity (5- to 6-fold) independent of RhoA binding [13,14]. The
lipids seem to bind to the regulatory C-terminus of ROCK, disrupt the
autoinhibitory interaction and thus lead to kinase activation.
Activation of ROCKs by truncation of the C-terminal autoinhibitory
part of the protein is occurring in vivo. During apoptosis caspase-3
cleaves ROCK I at the recognition site DETD and gives rise to an
constitutively active kinase [14] (Fig. 1B). This cleavage site is not
present in ROCK II. However, granzyme B, a proapoptotic protease,
can cleave the C-terminus of ROCK II thus also generating an active
enzyme [15]. Again this cleaving site is not present in ROCK I.
Negative regulators of ROCK activity have also been described. The
small GTPase RhoE binds to the N-terminal part of ROCK I and
interferes with binding of RhoA, thus preventing kinase activation
[16,17]. Two other small G-proteins, Gem and Rad, have also been
shown to bind to and thereby inhibit ROCKs but the detailed
mechanisms have to be further studied [17].2.3. ROCK targets
More than 15 ROCK substrates have been described of which some
are listed in Table 1. The most important targets for cardiovascular
function will be discussed in more detail (Fig. 2). A large number ofROCK targets are related to actin-ﬁlament dynamics, organization of
the cytoskeleton and regulation of contractility.
One of the most important substrates of Rho-kinases is the myosin-
phosphatase target unit (MYPT-1) of the myosin light chain phospha-
tase (MLCP) [18]. The MLCP consists of three different subunits: a
catalytic domain (protein phosphatase type 1), a myosin binding
subunit (MYPT-1) and a small non-catalytic subunit of unknown
function. NativeMLCP can be puriﬁed as a trimer consisting of this three
proteins [19]. Recently a small myosin phosphatase-RhoA interacting
protein (M-RIP)has beendiscovered [20].M-RIPbinds to bothRhoAand
MYPT-1 and might thereby target RhoA/ROCK to the MLCP [21].
Another recent study showed a direct binding of only ROCK II toMYPT-1
and also a major role of only ROCK II for vascular smooth muscle cell
contraction [22]. These are the ﬁrst results pointing towards a
differential function of ROCK I and ROCK II in smooth muscle cells.
Phosphorylation of MYPT-1 by ROCK II at various sites (threonine
696, serine 854 and threonine 853, numbering of the human isoform)
results in the inhibition of MLCP activity and a concomitant increase in
phosphorylated regulatory light chain of myosin (MLC) and smooth
muscle cell contractility ([23,24]. Under certain conditions, phos-
phorylation of MYPT-1 induces the dissociation of MYPT-1 and thus
MLCP from myosin in an agonist-speciﬁc manner thus hindering the
phosphatase to dephosphorylate MLC [25]. This also leads to an
increased phosphorylation state of MLC and to enhanced contractility
of the smooth muscle cell.
ROCK II also phosphorylate MLC directly at serine 19 in vitro [26]
but the relevance of this phosphorylation event has still to be
elucidated because activation of the Rho/Rho–kinase pathway
without concomitant activation of MLCK induces only minimal MLC
phosphorylation and cell contraction [27,28].
ROCK also phosphorylates CPI-17 [29], a small regulatory protein
that in its phosphorylated state inhibits MLCP activity by binding to
the phosphatase subunit of MLCP [30]. Phosphorylation of CPI-17 by
Table 1
Selected targets of ROCK.
Targets Effect Outcome Reference
Regulation of contractility
MYPT-1 Inhibition of MLCP activity Enhanced contractility/ stress ﬁber formation [18]
MLC Stimulation of actin-myosin ATPase activity Enhanced contractility/ stress ﬁber formation [26]
CPI-17 Inhibition of MLCP activity Enhanced contractility/ stress ﬁber formation [29]
Calponin Inhibition of calponin binding to actin Enhanced contractility [118]
Regulation of the cytoskeleton
Adducin Enhanced adducing/F-actin assembly Enhanced cell motility [119]
LIM-kinases 1 and 2 Stimulation of kinase activity Decreased actin-ﬁlament disassembly (via inactivation of coﬁlin) [120,121]
RhoE Increased RhoE stability Enhanced stress ﬁber disruption and Ras-induced transformation [33]
ZIPK Activation of ZIPK activity Enhanced stress ﬁber formation [122]
Proﬁlin Inhibition of Proﬁlin binding to actin Decreased Proﬁlin-induced actin remodelling [70]
Regulation of intermediate ﬁlaments
Vimentin Enhanced ﬁlament disassembly Cytokinesis? [123]
Regulation of signalling proteins
PTEN Stimulation of phosphatase activity Decreased intracellular PIP3 levels; tumor suppression [124]
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the inhibitory effect of CPI-17 on MLCP activity [32]. The relative
contribution of CPI-17 phosphorylation to ROCK-dependent contrac-
tion of smooth muscle has not been studied in detail yet.
Most ROCK substrates have been identiﬁed in in vitro-experiments
after activation of endogenous ROCK or transfection of one of the two
ROCK isoforms, in most cases ROCK II. For a long time it has been
assumed that because of thehigh identity of the kinasedomainsof ROCK
I andROCK II bothenzymes share the same substrates. RhoEwas theﬁrst
example for a ROCK target that is phosphorylated by ROCK I but not
ROCK II [33]. The abovementioned direct binding of ROCK II but not
ROCK I to MYPT-1 is another hint pointing to different functions of the
two isoforms [22]. Additional data from experiments with mice
haploinsufﬁcient for ROCK I or ROCK II in leucocyte recruitment and
neointima formation after vascular injury has also shown different
functions of the two kinases [34]. Haploinsufﬁcient ROCK Imice showed
signiﬁcantly reduced neointima formation and decreased level of
proinﬂammatory adhesion molecules after carotid artery ligation.
Interestingly, while blood pressure and heart rate are unchanged in
haploinsufﬁcient ROCK I and ROCK II mice [34,35], cardiac-speciﬁc
overexpression of RhoA leads to a dramatically depressed heart rate
[36]. Thus, at least in smoothmuscle tissue the two ROCK isoforms have
distinct roles under different conditions. A detailed analysis of speciﬁc
roles of individual ROCK isoforms is necessary to selectively target the
responsible ROCK enzyme in the therapy of cardiovascular disease.
3. ROCK and smooth muscle cells
The Rho/Rho-kinase pathway is an important regulator not only of
vascular smooth muscle cell contraction but also of migration,
proliferation and differentiation.
3.1. Contractility
The contractile state of VSMC is mainly determined by the
phosphorylation level of MLC. MLC is phosphorylated by the Ca2+/
calmodulin-dependent MLCK and dephosphorylated by the Ca2+-
independent MLCP. Various vasoactive agonists like angiotensin II,
endothelin-1 and thromboxane A2 activate G-protein coupled
receptors and lead not only to an increase in intracellular Ca2+ via
G-proteins of the Gq/G11-family but also activate G-proteins of the
G12/G13-family that stimulate the Rho/Rho-kinase signalling path-
way, thereby activating ROCK. Thus, as outlined above the inhibition
of MLCP via phosphorylation of MYPT-1 by ROCK leads to increased
phosphorylation of MLC and enhanced VSMC contractility [13,18]. In
addition, ROCK might also modulate VSMC contractility by direct
phosphorylation of the MLCP-inhibitory protein CPI-17 [29] and MLC
[18,26].Modulation of VSMC contractility via ROCK seems to be of par-
ticular importance during tonic contractions [37] in different vascular
beds including pulmonary artery, mesenteric artery and portal vein.
Another important role for ROCK has been shown for maintaining
myogenic tone of small arteries [38,39].
3.2. Migration
Migration of cells, including smooth muscle cells, depends on the
reorganization of the actin cytoskeleton. Involvement of ROCK in cell
migration has been extensively studied using pharmacological tools.
Depending on cell type and experimental conditions ROCK inhibition
can either inhibit or enhance cell migration. As several ROCK targets
are implicated not only in actin- but also intermediate ﬁlament
network- and microtubule-dynamics (see Table 1) the ﬁnal effect on
cell migration might depend on the relative contribution of each of
these pathways in a particular cell type.
Smooth muscle cell migration induced by PDGF and lysopho-
sphatidic acid can be attenuated by ROCK inhibitors or transfection of
a dominant-negative form of ROCK [40]. In addition, smooth muscle
cell migration in 3D collagen matrices is also inhibited by blocking
ROCK signalling [41]. In contrast, motility of differentiated aortic
smooth muscle cells is increased by inhibition of ROCK with fasudil, a
selective ROCK inhibitor [42]. These contradictory data might reﬂect a
differential importance of ROCKs depending on the differentiation
status of the smooth muscle cell.
3.3. Proliferation
Dysregulated proliferation of smoothmuscle cells can be one feature
of cardiovascular disease. ROCKs are implicated in the regulation of SMC
proliferation. As already seen for migration, proliferation stimulated by
PDGF is inﬂuenced by inhibition of the Rho/ROCK pathway [43].
Inhibition of ROCK abolishes the PDGF-induced activation of extracel-
lular-regulated kinases 1/2 (ERK 1/2). Similarly, ROCKsmight also play
a role in angiotensin II-induced vascular hypertrophy [44]. Opposite
data, that do not reveal a signiﬁcant role of ROCK in smooth muscle cell
proliferation, also exist. Some in vivo studies report no effect of ROCK
inhibition on smooth muscle cell proliferation after balloon injury
[45,46]. Again, the relative importance of the single ROCK substrates in a
distinct experimental setting might affect the ﬁnal observation after
interfering with the Rho/Rho-kinase pathway.
3.4. Differentiation
Smooth muscle cells unlike most other differentiated cells retain
the capacity to modulate their phenotype in response to certain
stimuli. The contractile phenotype of a smooth muscle cell is
Fig. 2. ROCK signalling in smooth muscle cells. The contractile state of smooth muscle cells is mainly determined by the phosphorylation level of the regulatory light chain of myosin
(MLC) which is regulated by the two enzymes myosin light chain kinase (MLCK) and myosin light chain phosphatase (MLCP). Binding of vasoconstrictors to G-protein coupled
receptors leads to activation of heterotrimeric G-proteins of the Gq/11- and G12/13 family. While Gq/11 via activation of PLC-β increases intracellular Ca2+ concentration and
concomitantly stimulates MLCK activity, activation of G12/13 leads to enhanced RhoA/ROCK activity and thus MLCP inhibition. Another mechanism for attenuating MLCP activity is
the phosphorylation and thereby activation of CPI-17 by ROCK. In addition, ROCK can directly phosphorylate MLC. Arachidonic acid is also capable of activating ROCK and inducing
the abovementioned signalling cascades leading to enhanced contractility. PLC, phospholipase C; Rho GEF, guanine nucleotide exchange factor; MYPT-1, myosin binding subunit;
PP-1c, protein phosphatase 1c.
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cytoskeletal genes that are regulated via serum-response factor (SRF)
[47]. Under certain conditions, e.g. vascular disease, this gene
expression pattern is switched to enhance growth and extracellular
matrix production leading to the so called synthetic phenotype of the
smooth muscle cell [47]. The Rho/Rho-kinase pathway seems to be
critically involved in the regulation of the smooth muscle phenotype.
Inhibition of ROCK by Y27632, a selective inhibitor of ROCK activity,
decreases the expression of contractile genes [48] whereas expression
of constitutively active RhoA increases the activity of smooth muscle-
speciﬁc promoters [49].
4. ROCK in cardiovascular disease
4.1. ROCK and hypertension
Hypertension is characterized by high arterial pressure resulting
from increased peripheral vascular resistance that can be attributed to
both enhanced contractility of vascular smooth muscle cells and
arterial wall remodelling. Increased activity of the Rho/Rho-kinase
pathway has been proposed to play an important role in the
development and maintenance of hypertension. In various animal
models of experimental hypertension a role of RhoA and ROCK has
been demonstrated. Blocking ROCK activity with Y27632 has bloodpressure lowering effects in spontaneously hypertensive rats (SHR),
deoxycorticosterone-acetate (DOCA)/salt-treated and renal hyper-
tensive rats [50]. In contrast, treatment of normotensive rats with the
ROCK inhibitor leads to an only small transient decrease in blood
pressure. Similarly, oral administration of fasudil to SHR rats
signiﬁcantly lowered blood pressure [51]. In addition, several studies
have addressed changes in RhoA activity in isolated vascular segments
from hypertensive animals suggesting that increased RhoA activity is
responsible for enhanced ROCK function in the pathology of
hypertension. In mesenteric and cerebral arteries from SHR and
normotensive rats the relaxation induced by treatment with Y27632
was markedly higher in arteries from SHR rats [52,53]. This has also
been shown for mesenteric arteries from DOCA/salt-treated rats
[54]. In animals treated with L-NAME, an inhibitor of NO-synthase,
oral administration of Y27632 lowered blood pressure [55] and the
level of active, GTP-bound RhoA was markedly increased in vessels
from L-NAME treated rats. Similarly, direct evidence for increased
amounts of active RhoA have also been found in stroke-prone SHR,
DOCA/salt- and renal hypertensive rats [55–57]. Analysis of the
expression levels of RhoA has led to controversial results with some
studies showing an increased expression of RhoA under hypertensive
conditions [56] whereas in other reports no differences in the
expression proﬁle of proteins from the RhoA/ROCK pathway have
been detected [55].
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hypertensive conditions. Arteries from DOCA/salt-hypertensive rats
develop spontaneous tone that is not observed in vessels from
normotensive rats [58]. Treatment with Y27632 signiﬁcantly reduces
this tone development in arteries from hypertensive rats but has no
impact on basal tone of normotensive rats.
Not only oral but also direct central administration of ROCK
inhibitor has an impact on blood pressure [59,60]. Central application
of Y27632 to SHR and L-NAME hypertensive rats lowered blood
pressure and reduced enhanced sympathetic activity. Again, both
membrane-bound RhoA and Rho-kinase activity in the brainstem of
these hypertensive animals was increased.
Alterations in the RhoA/ROCK pathway are most likely the
consequence of an upstream event in the hypertensive state. One
upstream signalling molecule that seems to be involved is angiotensin
II and its receptor type 1 (AT1). Y27632 has been shown to be more
potent in relaxing arteries from angiotensin II-induced hypertensive
compared to normotensive animals [61] pointing towards an
increased sensitivity to ROCK inhibition in these animals. Speciﬁc
blockade of AT1 receptor prevents the upregulation of RhoA and ROCK
activity in different models of experimental hypertension [57,62]. In
addition, in arteries from stroke-prone SHR increased mRNA levels
of several RhoGEFs that function as activators for RhoA have been
detected thereby linking G-protein coupled receptor signalling to
enhancedRhoAandROCKactivity [63]. Indeed, a recent study revealed
the essential role of the signalling from heterotrimeric G-proteins
via RhoGEF (LARG) to RhoA/ROCK pathway [64].With an inducible and
smoothmuscle speciﬁc conditional knockoutmouse line that allows for
the deletion of either Gαq/11 or Gα12/13 experimental DOCA/salt-
hypertension was analysed. Inmice lacking either of the two families of
signalling molecules the development as well as the maintenance of
DOCA/salt-induced hypertension was completely abolished. The same
was also seen in mice deﬁcient for the RhoGEF LARG [64].
Another upstream event that is linked to activation of RhoA and
ROCKs in hypertension is the formation of reactive oxygen species
(ROS). Oxidative stress characterizes different forms of hypertension
in animals and humans [65,66]. It has been shown that rat aorta
contracted under conditions that induce ROS formation has an
increased sensitivity towards Y27632 [67] pointing towards an
activation of the RhoA/ROCK pathway by ROS [62]. Indeed, the
amount of membrane bound, active RhoA was increased by ROS. Air
pollution is an environmental factor that is known to potentiate
hypertension in humans [68]. A recent study could show that exposure
of rats to air pollution in combination with angiotensin II-infusion
leads to an increase in blood pressure that is accompanied by a ROS-
mediated increase in ROCK activity andMYPT-1 phosphorylation [69].
As outlined above, ROCKs not only inﬂuence VSMC contraction but
have a more general impact on actin dynamics thereby also inﬂuencing
proliferation and migration of vascular smooth muscle cells. Over-
expressionof proﬁlin1, a small actinbindingprotein thathas been shown
to be a ROCK target (Table 1) [70], in blood vessels of mice increased
stress ﬁber formation and induced hypertrophy [71]. Furthermore,
proﬁlin 1 led to an elevated blood pressure in adult animals that was
accompanied by increased ROCK II expression. Thus, at long sight, pro-
found changes in the actin cytoskeleton that primarily induced hyper-
trophy can directly inﬂuence vascular smooth muscle cell contractility.
Other cardiovascular disorders (e.g. atherosclerosis) that often
accompany hypertensionmight also be in part due to changes in RhoA
and ROCK activity. Indeed, long-term blockade of ROCK with a
nonhypotensive dose of fasudil suppresses medial hypertrophy and
perivascular ﬁbrosis in coronary arteries from SHR and angiotensin II-
treated hypertensive rats [51,72].
A role for enhanced ROCK activity in clinical hypertension has also
been reported [73]. Forearmbloodﬂowwasmeasured in normotensive
and hypertensive subjects. In hypertensive patients, resting forearm
vascular resistance was higher compared to normotensive subject.Graded intra-arterial infusion of fasudil increased forearm blood ﬂow
and this decrease in vascular resistance was more pronounced in
hypertensive patients. If sodium nitroprussid was used instead of
fasudil the vasodilator responses did not differ between the two groups
of patients. This leads to the conclusion that enhanced activity of the
RhoA/ROCK pathway is involved in the increased vascular resistance in
clinical hypertension. Furthermore, in patients with heart failure intra-
arterial infusionwith fasudil decreases vascular forearm resistance and
increases forearm blood ﬂow [74]. Interestingly, in cigarette smokers, a
high risk group for developing cardiovascular disease, increased RhoA
and ROCK activity in forearm vasculature has been reported [75].
Another evidence for the importance of the RhoA/ROCK pathway for
hypertension in humans comes from genetic studies [76,77]. For ROCK
II a polymorphism exists at amino acid position 431 that can be either
threonine or asparagine (Asn) [76]. This amino acid is located in the
coiled-coil region of ROCK II and might therefore be involved in ROCK
dimerization, Rho binding and thus ROCK activity and phosphorylation
of ROCK targets. The Asn/Asn genotype has been shown to be
associated with a greater resting systolic blood pressure and a higher
blood pressure increase after applying environmental (cold) stress.
These effects seem to be due to an increased vascular resistance as
cardiac output, large artery compliance and vasoactive hormone
metabolism are unchanged. A second study provides further evidence
that ROCK polymorphismmight be involved in blood pressure control.
A haplotype block consisting of four SNPs within the ROCK II allele was
found to be recessively associated with a lower risk of hypertension
[77]. This block is located at the 5'-end of the ROCK II locus and covers
exons encoding the kinase domain of the enzyme.
4.2. ROCK and NO signalling
Nitric oxide (NO) derived from the endothelium is a potent
vasodilator. NO, after diffusing into the smooth muscle cells of the
vessels, activates soluble guanylate-cyclase and thus stimulates the
formation of cyclic GMP (cGMP) and the subsequent activation of
cGMP-dependent protein kinase (cGK). The vasodilation induced by the
NO/cGK signalling cascade results from a decrease in intracellular Ca2+
due to several mechanisms like phosphorylation of ion channels and
activation of the sarcoplasmatic Ca2+-ATPase [78] as well as a reduced
Ca2+ release from intracellular stores via phosphorylation of IRAG [79]
and phosphorylation and activation of myosin phosphatase [80].
Impaired endothelial function and decreased NO-production has
been implicated in the etiology of hypertension. Decreased expression
of endothelial nitric oxide synthase (eNOS) is found in aortas from SHR
rats [81] and eNOS-deﬁcientmice have an elevatedbloodpressure [82].
Interestingly, there seems to be extensive crosstalk between NO-
and RhoA/ROCK-signalling (Fig. 3). There is compelling evidence that
the NO/cGK pathway leads to an inhibition of RhoA/ROCK signalling.
The NO-donor sodium nitroprussid and constitutively active cGK are
able to inhibit the phenylephrine-induced translocation of RhoA from
the cytosolic fraction to the membrane in rat aorta [83] thus
abolishing subsequent ROCK activation. Furthermore, NO-mediated
vasorelaxation has been demonstrated to be in part mediated by
inactivation of RhoA/ROCK signalling in rat aorta [84]. Chronic and
acute inhibition of NOS increases α2-adrenoreceptor-stimulated
activation of RhoA and ROCK [85] showing once more the capability
of NO-signalling to inhibit the RhoA/ROCK cascade.
On the other hand, the RhoA/ROCK cascade seems to reciprocally
inﬂuence NO-signalling. Inhibition of RhoA function by HMG-CoA
reductase inhibitors (“statins”), like ﬂuvastatin or mevastatin,
upregulates NOS expression [86,87] and leads to increased NO
production and reduced vascular contractility [88]. Blocking ROCK
function with fasudil also results in increased NO production [89]. The
mechanism by which ROCK inﬂuences NO production seems to be the
regulation of eNOS mRNA stability. Hypoxia and thrombin, two
stimuli that increase ROCK activity, downregulate eNOS expression
Fig. 3. NO and statins in ROCK signalling. Endothelium-derived nitric oxide (NO) stimulates synthesis of cyclic GMP (cGMP) and leads to activation of cGMP-dependent protein kinase
(cGK) in smoothmuscle cells. Active cGK interferes with the translocation of RhoA from the cytosol to themembrane thereby preventing RhoA and subsequently ROCK activation. Statins
increase eNOS activity and expression. Furthermore, by blocking the synthesis of geranylgeranyl-pyrophosphate statins prevent RhoA binding to the membrane. In contrast, RhoA/ROCK
has an inhibitory impact on NO-signalling leading to decreased NO-levels.
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inhibition of ROCK by e.g. Y27632 increases eNOS mRNA half life
and expression [92].
Taken together, increased NO production will lead to an inhibition
of the RhoA/ROCK-cascade thus protecting against the enhanced
contractile and proliferative effects of RhoA/ROCK signalling. On the
other hand, stimulated RhoA/ROCK-activity appears to diminish NO
production thus even amplifying the increase in contractility induced
by RhoA/ROCK-signalling.
5. Targeting the RhoA/ROCK signalling cascade in the treatment of
cardiovascular disease
5.1. ROCK inhibitors
Several compounds have been developed and described to
speciﬁcally inhibit ROCK activity with some speciﬁcity. The most
widely used inhibitor is the pyridine derivative Y27632 that competes
for the ATP binding site on the ROCKs thus inhibiting the kinase
activity [93]. Thereby it prevents MYPT-1 phosphorylation and
inhibits smooth muscle contraction. Y27632 is transported into the
cells via a carrier-facilitated diffusion mechanism so that extra- and
intracellular concentrations of the compound are similar. Y27632 has
no speciﬁcity for ROCK isoforms but inhibits both ROCK I and ROCK II.
Although Y27632 is reasonably selective for the Rho-kinases and has
much lower inhibitory effects on PKC, PKA and MLCK it shows a
similar potency for the also Rho-dependent PCK-related kinase I (PRK
2) in vitro [94]. Nevertheless Y27632 remains an important pharma-
cological tool for analysing the involvement of ROCK in cardiovascular
processes under normal and pathological conditions.
Another group of compounds that are derived from isoquinolinesul-
fonamide shows a similar selectivity for inhibition of ROCK. Fasudil, or
HA1077, also competeswithATP forbinding to thekinase [94]. In addition
to Y27632 fasudil also exerts inhibitory effects on PKA and PKC but the
IC50-values are approximately 5 and 30 times (∼5 µmol/l and 37 µmol/l,
respectively) higher than for the ROCKs (IC50 ∼ 1 µmol/l) [95]. It has also
been demonstrated that hydroxyfasudil, a major active metabolite offasudil after oral administration, has a more speciﬁc inhibitory effect on
ROCKwith the IC50 being∼0.7 µmol/l [72,96]. Fasudil hydrochloride is in
clinical use in Japan for several years for the treatment of cerebral
vasospasm following subarachnoid haemorrhage [97]. In addition, an
anti-anginal effect of fasudil in patients with stable angina pectoris has
been observed in clinical trials [98,99]. Both studies have proven that
long-termoral treatmentwith fasudil iswell tolerated anddoes not cause
major adverse events. In patients suffering from vasospastic angina,
intracoronary application of fasudil attenuates both arterial spasm and
the extent of subsequent myocardial ischemia [100,101]. Intravenous
administration of fasudil in the acute phase of stroke has demonstrated
beneﬁcial effects of ROCK inhibition on ischemic neuronal damage [102].
In patients with severe pulmonary hypertension intravenous adminis-
trationof fasudil signiﬁcantly lowerspulmonaryvascular resistance [103].
Furthermore, fasudil suppresses the excessive proliferation of pulmonary
artery smooth muscle cells, a key feature in the development of
pulmonary hypertension, in vitro [104]. Currently clinical phase III trials
for the therapy of Raynaud's syndrome (NCT00498615) and carotid
stenosis (NCT00670202) with fasudil are ongoing.
More recently a novel class of compounds has been developed.
This aminofurazan-based inhibitors (GSK269962A and SB772077B)
show similar inhibitory effects on ROCK I and ROCK II but with a
higher potency than Y27632 [105]. Both drugs act as vasodilators and
lower blood pressure in animal models of hypertension. Other new
developed ROCK inhibitors like Wf536 [106] and Y39983 [107] are
supposed to be effective in treating cancer or glaucoma.
Efforts are underway to develop more speciﬁc and potent ROCK
inhibitors that can be used for clinical applications. Taking in account
that the two ROCK isoforms seem to have different functions in
smooth muscle cells under different conditions [22,34] the develop-
ment of isoform speciﬁc inhibitors is of interest and may allow for a
more targeted intervention. Modiﬁcation of fasudil led to the
compound H1152P, a potent and speciﬁc inhibitor of ROCK II with
weaker inhibitory effects on other kinases, e.g. PKA, PKC [108]. In
addition, SLx-2119, a selective ROCK II inhibitor, has been described
[109,110]. This compound has shown promise in cancer models as
well as models of ﬁbrosis without adverse hemodynamic side effects.
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HMG-CoA reductase inhibitors or “statins” are used clinically to
lower elevated cholesterol plasma levels. However, even in normo-
cholesterolemic individuals statins can exert beneﬁcial cardiovascular
effects. This is due to pleiotropic effects of statins on cardiovascular
function including improvement of endothelial function, reduction of
oxidative stress and anti-inﬂammatory actions and have been
reported in animal as well as clinical studies [111]. Indeed, one
study in humans could prove pleiotropic effects of statins indepen-
dent from cholesterol lowering [112]. Treatment of patients with
simvastatin improved endothelial function at least in part by reducing
oxidative stress without changing LDL cholesterol levels. Further-
more, early beneﬁcial effects of statins on oxidative stress, proinﬂam-
matory cytokines and endothelial activation have been observed very
rapidly (after 2 h) before changes in the lipid proﬁle could occur [113].
By blocking cholesterol biosynthesis, statins also prevent the
formation of isoprenoid intermediates like geranylgeranyl pyrophos-
phate (GGPP). Isoprenylation of RhoA with GGPP is essential for
activation of RhoA by facilitating membrane localisation of the GTPase
where GDP-GTP exchange takes place [114]. The prevention of this
membrane interaction leads to inactivation of RhoA and thus ROCKs.
Indeed, the comparison of a high-dose statin monotherapy with a
combination of low-dose statin plus ezetimibe could show that even
though both treatments lead to comparable changes in the lipid
proﬁle only the high-dose statin monotherapy has a direct impact on
RhoA/ROCK signalling and lowers ROCK activity [115].
As mentioned above NO- and RhoA/ROCK-signalling display an
extensive crosstalk and antipodal inﬂuence on their activities. Indeed,
treatment with statins leads to increased eNOS expression and
increased endothelial NO levels, an effect that can be blocked by GGPP
[86]. Statins not only exert effects on eNOS expression levels but also
rapidly inﬂuence eNOS activity. Statins promote the phosphorylation
and thus activation of eNOS in endothelial cells [116], an effect than can
be mimicked by RhoA/ROCK inhibition [89].
Indeed, several of the cardiovascular effects of statins are eNOS
dependent and are absent in eNOS-deﬁcient mice [117] or after eNOS
inhibition by L-NAME [88].
As abnormal activity of the RhoA/ROCK signalling cascade is
supposed to be critically involved in several cardiovascular diseases,
the ability of statins to inhibit RhoA activity might be a key factor in
the beneﬁcial pleiotropic effects of statins for cardiovascular function.
6. Concluding remarks
There is compelling evidence for the Rho/ROCK signalling cascade to
be critically involved in regulating smooth muscle contractility and
numerous studies have shown that abnormalities in ROCK activity play
an important role in cardiovascular disease and especially hypertension.
There has been much effort to understand ROCK signalling in vascular
smooth muscle cells in detail and several inhibitors of ROCK have been
synthesised. One of them, fasudil, already reached the clinic for
treatment of different cardiovascular disease and tests for additional
indications are ongoing. The Rho/ROCK cascade seems to be interacting
with other signalling cascades, like NO-signalling, that are also im-
portant regulators of vascular smooth muscle contractility. Therefore,
targeting the critically involved ROCK isoform under speciﬁc cardiovas-
cular pathophysiological conditions might have multiple beneﬁcial
effects on vascular function.
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